CNTB News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$56.9M

Volume

548.34K

Next Earnings

November 11th

Mkt Cap

$57.1M

Volume

548.34K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business UpdateConnect Biopharma reported Q1 2026 financial results and provided updates on its Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD. The independent Data Monitoring Committee confirmed no safety concerns and adequate study power, with topline data expected mid-2026. The company closed a $20.2 million private placement and has $46 million in cash, sufficient to fund operations into H2 2027. Positive Phase 1 IV rademikibart data showed rapid lung function improvements within 15 minutes.GlobeNewswire Inc. · May 12, 2026

Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025Connect Biopharma will present two poster presentations at the ERS Congress 2025 about rademikibart, a monoclonal antibody targeting IL-4Rα for treating asthma and inflammatory diseases.GlobeNewswire Inc. · Sep 4, 2025

Connect Biopharma Posts Q2 Revenue DropConnect Biopharma reported a significant revenue drop from $24.1 million to $48,000 in Q2 2025, increased R&D expenses, and a net loss of $12.9 million. The company continues developing rademikibart for inflammatory diseases and is progressing clinical trials.The Motley Fool · Aug 13, 2025

Connect Biopharma to Participate in the BTIG Virtual Biotechnology ConferenceConnect Biopharma will present at the BTIG Virtual Biotechnology Conference on July 29th, 2025, discussing their clinical-stage development of rademikibart, an antibody targeting IL-4Rα for treating asthma and COPD.GlobeNewswire Inc. · Jul 18, 2025

Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual CongressConnect Biopharma presented positive data on its investigational drug rademikibart, which showed significant improvements in lung function and reduced asthma exacerbations in patients with eosinophilic-driven type 2 asthma.GlobeNewswire Inc. · Jun 13, 2025

Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual CongressConnect Biopharma, a clinical-stage biopharmaceutical company, announced two oral presentations at the EAACI 2025 Annual Congress. The presentations will focus on the efficacy and safety of their lead drug candidate, rademikibart, in treating eosinophilic-driven, type 2 asthma.GlobeNewswire Inc. · Jun 3, 2025

Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics ForumSAN DIEGO, CA and TIACANG, China, July 01, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that Barry Quart, Chief Executive Officer, David Szekeres, President and Steven Chan, Chief Financial officer will be hosting one-on-one investor meetings at the Leerink Partners Inflammation and Immunology (I&I) and Metabolism Therapeutics Forum, taking place on July 9-10, 2024 in Boston, MA.GlobeNewswire Inc. · Jul 1, 2024

Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that the Board of Directors (Board), including all of the independent directors of the Board, granted to Barry Quart, Pharm.D., the Company’s newly-appointed Chief Executive Officer, and David Szekeres, the Company’s newly-appointed President, non-qualified stock option awards to purchase an aggregate of 2,658,734 ordinary shares and 1,772,489 ordinary shares, respectively, under the Connect Biopharma Holdings Limited 2024 Employment Inducement Incentive Award Plan (the Inducement Plan). The options were granted effective June 12, 2024 and have an exercise price of $1.77 per share (the closing price of Connect’s ordinary shares on the grant date). The options vest over a period of four years, with 25% vesting on June 12, 2025 and the remaining shares vesting in equal monthly installments thereafter, subject to each executive’s continued employment or service. The awards were granted as inducements material to Dr. Quart and Mr. Szekeres entering into employment with Connect in accordance with Nasdaq Listing Rule 5635(c)(4).GlobeNewswire Inc. · Jun 12, 2024

Connect Biopharma Announces New Leadership and Chair of the Board of DirectorsSAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today the appointments of Barry Quart, Pharm.D., as Chief Executive Officer (CEO) and Director, David Szekeres as President, and Kleanthis G. Xanthopoulos, Ph.D., as the new Chair of the Board of Directors (Board).GlobeNewswire Inc. · Jun 12, 2024

Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe AsthmaSAN DIEGO, CA and TAICANG, China, May 22, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that Edward Kerwin, M.D. presented a late-breaking poster presentation on the positive results from the rademikibart global Phase 2b trial in patients with moderate-to-severe asthma at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024 in San Diego, CA.GlobeNewswire Inc. · May 22, 2024

CNTBConnect Biopharma Holdings Limited Ordinary Shares

CNTB

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any CNTB yet.

Related Tickers

Earnings

Mkt Cap

$56.9M

Volume

548.34K

Next Earnings

November 11th